Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
07:00am, Friday, 17'th Oct 2025
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency's Committee for Medicinal Products for
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
06:00am, Thursday, 16'th Oct 2025
CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced
ITM Appoints Annette Breunig as Chief People Officer
05:00am, Monday, 13'th Oct 2025
Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief Pe
BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform
08:00am, Wednesday, 08'th Oct 2025
TORONTO--(BUSINESS WIRE)--BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform.
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)
05:09am, Sunday, 05'th Oct 2025
Sanofi is repositioned as a pure pharma play. Following an earnings reset, we see support in ongoing buybacks and higher sales guidance. Q2 results showed strong Dupixent growth, and 2026 readouts off
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
08:00am, Thursday, 02'nd Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
10:42am, Wednesday, 01'st Oct 2025
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials
07:00am, Wednesday, 01'st Oct 2025
TEL AVIV, Isreal & CAMBRIDGE, Mass.--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of g
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
02:37pm, Friday, 26'th Sep 2025
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu
Sanofi Expands Insulin Savings Program To Cover All US Patients
01:40pm, Friday, 26'th Sep 2025
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: S
Sanofi to offer all insulin products for $35 per month in US
08:26am, Friday, 26'th Sep 2025
French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status.
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
08:00am, Friday, 26'th Sep 2025
MORRISTOWN, N.J. , Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all pa
French court orders Sanofi to pay $177 million for anti-competitive behaviour
08:49am, Wednesday, 24'th Sep 2025
A Paris court on Wednesday ordered Sanofi and its Winthrop unit to pay 150.7 million euros ($177.1 million) in damages to France's national health insurance fund (CNAM) for anti-competitive practices
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di
